Patient Under 5 Years Old
There is limited experience with the administration of Pulmozyme in patients under five, so its use should be considered only for those patients in whom there is a potential for benefit in lung function or in risk of respiratory tract infections.
To learn more about the safety of Pulmozyme in pediatric patients, one study assessed its use in two age groups: younger patients (three months to less than five years of age) and older patients (five years to less than 10 years of age).
- In this study, side effects were generally similar in both age groups.
- There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients.
- The kind of side effects reported was similar to that of Pulmozyme when used in larger trials that studied older patients.
Trials or studies demonstrating efficacy in Pulmozyme in patients <5 have not been conducted.
Data in studies conducted in the adult setting cannot be extrapolated to patients <5.
Your CF Care Team is the best source of information about CF and Pulmozyme. Talk to your doctor if you have questions or to see if Pulmozyme is right for your child.